# Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

> **NCT07179159** · NA · RECRUITING · sponsor: **Yanqing Li** · enrollment: 372 (estimated)

## Conditions studied

- HELICOBACTER PYLORI INFECTIONS

## Interventions

- **DRUG:** 14-day vonoprazan-amoxicillin dual therapy
- **DRUG:** 14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy
- **DRUG:** 14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy

## Key facts

- **NCT ID:** NCT07179159
- **Lead sponsor:** Yanqing Li
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 372 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07179159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07179159, "Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07179159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*